HSP90B2P and hepatocellular carcinoma: Sorafenib is an effective clinical drug in the treatment of hepatocellular carcinoma (HCC) and GRP78 (a member of the HSP family) which is overexpressed in sorafenib resistant cancer cells compared to sensitive cells.